アトピー性皮膚炎市場：薬剤クラス別、投与経路別、流通チャネル別-2025-2030年の世界予測

アトピー性皮膚炎市場は、2023年に63億8,000万米ドルと評価され、2024年には67億4,000万米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には95億3,000万米ドルに達すると予測されています。

アトピー性皮膚炎（AD）は、強いかゆみと再発性の湿疹性病変を特徴とする慢性炎症性皮膚疾患であり、世界人口のかなりの部分が罹患しています。この疾患の範囲は皮膚科学にとどまらず、アレルギー学、免疫学、さらには心理的影響によるメンタルヘルスにまで及んでいます。有病率が上昇するにつれて市場の必要性が生じ、効果的な治療に対する要求が急増します。そのため、AD治療は皮膚科学や医薬品のポートフォリオに欠かせないものとなっています。その用途は、外用薬や経口薬から生物製剤やモノクローナル抗体のような新しい治療薬まで多岐にわたる。エンドユーザーは主にヘルスケアプロバイダー、皮膚科クリニック、調査、ADによるQOLの問題に悩む患者などです。市場開拓は、医療費の増加、認知度の向上、個別化医療や生物製剤を含む医薬品開発の進歩に影響されています。非ステロイド性治療や、より安全で長期的なコントロールオプションに対するアンメットニーズには大きなビジネスチャンスがあります。遺伝的起源や環境的誘因を探求するための研究機関との提携は、潜在的な成長経路を提供します。特筆すべき機会としては、デジタルヘルスツールを活用した遠隔モニタリングと管理があり、患者の治療レジメン遵守を確実にします。逆に限界としては、先進治療の高額な費用、保険適用の課題、ステロイドの長期使用に伴う副作用などが挙げられます。また、ジェネリック医薬品との競合と相まって、新規治療に対する規制上のハードルも課題となっています。技術革新が必要な分野としては、新しいドラッグデリバリーシステムの開発、微生物を標的とした治療法の探求、根本的な炎症経路を特異的に標的とする生物学的製剤の進歩などが挙げられます。市場はダイナミックで競合情勢にあり、先を行くためには継続的な研究開発が必要です。企業は、皮膚科学、免疫学、デジタルヘルスなどの知見を取り入れた学際的なアプローチに注力し、症状を緩和するだけでなく、疾患の根源に効率的に対処し、患者のQOLと事業の成長を向上させる総合的なソリューションを構築する必要があります。

市場力学：急速に進化するアトピー性皮膚炎市場の主要市場インサイトを公開

アトピー性皮膚炎市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • アトピー性皮膚炎の発生率の増加
  • アトピー性皮膚炎を激化させる食物アレルギーの有病率の増加
  • 皮膚バリア保護作用のある新規保湿剤、生物製剤、脂質補充外用薬の開発
• 市場抑制要因
  • 治療薬の高コスト
• 市場機会
  • 治療法に対する意識の高まり
  • 様々な発展途上国における治療へのアクセスの開発
• 市場の課題
  • 投薬に伴う副作用

ポーターのファイブフォース：アトピー性皮膚炎市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アトピー性皮膚炎市場における外部からの影響の把握

外部マクロ環境要因は、アトピー性皮膚炎市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アトピー性皮膚炎市場における競合情勢の把握

アトピー性皮膚炎市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアトピー性皮膚炎市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アトピー性皮膚炎市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アトピー性皮膚炎市場における成功への道筋を描く

アトピー性皮膚炎市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • アトピー性皮膚炎の発生率増加
    • 食物アレルギーの増加が深刻化アトピー性皮膚炎
    • 皮膚バリア保護効果のある新規保湿剤、生物製剤、脂質補給外用薬の開発
  • 抑制要因
    • 治療費の高騰
  • 機会
    • 病気の治療法の入手可能性に関する意識の高まり
    • さまざまな新興諸国で治療へのアクセスが拡大
  • 課題
    • 薬の使用に伴う副作用
• 市場セグメンテーション分析
  • 薬物クラス：より高い有効性と最小限の副作用を持つ阻害剤の大きな利点
  • 流通チャネル：宅配サービスや割引によりオンライン薬局の好感度が高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アトピー性皮膚炎市場薬剤クラス別

• 生物学的製剤
• カルシニューリン阻害剤
• コルチコステロイド
• PDE-4阻害剤

第7章 アトピー性皮膚炎市場：投与経路別

• 注射可能
• オーラル
• 話題

第8章 アトピー性皮膚炎市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカのアトピー性皮膚炎市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のアトピー性皮膚炎市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのアトピー性皮膚炎市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ジョンソン・エンド・ジョンソン、プロテオロジックスを戦略的に買収し、アトピー性皮膚炎と喘息治療の選択肢を強化
  • イーライリリーのレブリキズマブがアトピー性皮膚炎の有色人種の皮膚に有効性を実証
  • グレンマークとファイザーがインドで新たなアトピー性皮膚炎治療を導入
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Biofrontera AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Galderma S.A.
• GlaxoSmithKline PLC
• LEO Pharma A/S
• Meda AB
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. ATOPIC DERMATITIS MARKET RESEARCH PROCESS
• FIGURE 2. ATOPIC DERMATITIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ATOPIC DERMATITIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ATOPIC DERMATITIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ATOPIC DERMATITIS MARKET DYNAMICS
• TABLE 7. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY PDE-4 INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ATOPIC DERMATITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ATOPIC DERMATITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. ATOPIC DERMATITIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. ATOPIC DERMATITIS MARKET, FPNV POSITIONING MATRIX, 2023

The Atopic Dermatitis Market was valued at USD 6.38 billion in 2023, expected to reach USD 6.74 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 9.53 billion by 2030.

Atopic dermatitis (AD), a chronic inflammatory skin disease characterized by intense itching and recurrent eczematous lesions, affects a significant portion of the population globally. The condition's scope extends beyond dermatology, impacting allergology, immunology, and even mental health due to its psychological effects. Market necessity arises as prevalence increases, and the requirement for effective treatment catapults. This makes AD treatment an indispensable part of dermatological and pharmaceutical portfolios. Applications span from topical and oral pharmaceuticals to biologics and emerging therapies like monoclonal antibodies. End-users primarily include healthcare providers, dermatology clinics, researchers, and patients struggling with quality-of-life issues due to AD. Market growth is influenced by increased healthcare expenditure, rising awareness, and advancements in drug development, including personalized medicine and biologics. A significant opportunity lies in the unmet needs for non-steroidal treatments and safer, long-term control options. Partnerships with research institutes to explore genetic origins and environmental triggers offer potential growth pathways. A notable opportunity involves leveraging digital health tools for remote monitoring and management, ensuring patient adherence to treatment regimens. Conversely, limitations include the high cost of advanced treatments, insurance coverage challenges, and adverse side effects associated with long-term steroid use. Regulatory hurdles for new therapies also pose a challenge, coupled with competition from generic products. Areas ripe for innovation include the development of new drug delivery systems, exploration of microbiome-targeted therapies, and advances in biologics that specifically target underlying inflammatory pathways. The market presents a dynamic and competitive landscape, with continuous research and development required to stay ahead. Companies should focus on multidisciplinary approaches, incorporating insights from dermatology, immunology, and digital health to craft holistic solutions that not only alleviate symptoms but address the roots of the disease efficiently, enhancing patient quality of life and business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Atopic Dermatitis Market

The Atopic Dermatitis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing incidence of atopic dermatitis
  • Growing prevalence of food allergies intensifying atopic dermatitis
  • Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
• Market Restraints
  • High cost of therapeutics
• Market Opportunities
  • Rising awareness regarding the availability of treatments for the disease
  • Growing access to treatment in various developing countries
• Market Challenges
  • Adverse effects associated with the use of medication

Porter's Five Forces: A Strategic Tool for Navigating the Atopic Dermatitis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Atopic Dermatitis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Atopic Dermatitis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Atopic Dermatitis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Atopic Dermatitis Market

A detailed market share analysis in the Atopic Dermatitis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Atopic Dermatitis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Atopic Dermatitis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Atopic Dermatitis Market

A strategic analysis of the Atopic Dermatitis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Atopic Dermatitis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biofrontera AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Galderma S.A., GlaxoSmithKline PLC, LEO Pharma A/S, Meda AB, Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Atopic Dermatitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Biologics, Calcineurin Inhibitors, Corticosteroids, and PDE-4 Inhibitor.
• Based on Route of Administration, market is studied across Injectable, Oral, and Topical.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of atopic dermatitis
    • 5.1.1.2. Growing prevalence of food allergies intensifying atopic dermatitis
    • 5.1.1.3. Development of novel moisturizers that confer skin-barrier protection, biologics, and lipid-replenishing topical drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising awareness regarding the availability of treatments for the disease
    • 5.1.3.2. Growing access to treatment in various developing countries
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with the use of medication
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Significant benefits of inhibitors with higher efficacy and minimal side effects
  • 5.2.2. Distribution Channel: Growing preferences for online pharmacies owing to home delivery services and discounts
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Atopic Dermatitis Market, by Drug Class

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Calcineurin Inhibitors
• 6.4. Corticosteroids
• 6.5. PDE-4 Inhibitor

7. Atopic Dermatitis Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Topical

8. Atopic Dermatitis Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Atopic Dermatitis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Atopic Dermatitis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Atopic Dermatitis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Johnson & Johnson's Strategic Acquisition of Proteologix to Enhance Atopic Dermatitis and Asthma Treatment Options
  • 12.3.2. Eli Lilly's Lebrikizumab Demonstrates Efficacy in Skin of Color for Atopic Dermatitis
  • 12.3.3. Glenmark and Pfizer Introduce New Atopic Dermatitis Treatment in India
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Astellas Pharma Inc.
• 3. Bausch Health Companies Inc.
• 4. Bayer AG
• 5. Biofrontera AG
• 6. Bristol-Myers Squibb Company
• 7. Eli Lilly and Company
• 8. F. Hoffmann-La Roche Ltd.
• 9. Galderma S.A.
• 10. GlaxoSmithKline PLC
• 11. LEO Pharma A/S
• 12. Meda AB
• 13. Mylan N.V.
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. Regeneron Pharmaceuticals, Inc
• 17. Sanofi S.A.
• 18. Teva Pharmaceutical Industries Ltd.